Docoh
Loading...
Sign up Log in

ACUR Acura Pharmaceuticals

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935 and is headquartered in Palatine, IL.

Company profile

Ticker
ACUR
Exchange
NASDAQ
Website
www.acurapharm.com
CEO
Robert B. Jones
Employees
Incorporated
New York
Location
Illinois
Fiscal year end
Dec 31
Sector
Health Technology > Pharmaceuticals: Generic
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott • Abbvie ...
Former names
HALSEY DRUG CO INC/NEW
SEC CIK
0000786947
Corporate docs
IRS number
110853640

ACUR stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 Nov 20
28 Feb 21
31 Dec 21

Financial summary

Financial statements Chart ACUR financial data
Quarter (USD)
 Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 493K 493K 493K 493K 493K 493K
Cash burn (monthly) 181.67K (positive/no burn) 226K 45.08K 181.67K 3.25K
Cash used (since last report) 905.25K n/a 1.13M 224.65K 905.25K 16.19K
Cash remaining -412.25K n/a -633.16K 268.35K -412.25K 476.81K
Runway (months of cash) -2.3 n/a -2.8 6.0 -2.3 146.7

Beta Read what these cash burn values mean

Recent insider trades

ACUR insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
24 Feb 21 Peter A Clemens Common Stock Payment of exercise Dispose F No No 0.4 15,100 6.04K 416,097
24 Feb 21 Peter A Clemens Common Stock Option exercise Aquire M No No 0.151 40,000 6.04K 431,197
24 Feb 21 Peter A Clemens Stock options Common Stock Option exercise Dispose M No No 0.151 40,000 6.04K 0
24 Feb 21 James F Emigh Common Stock Payment of exercise Dispose F No No 0.4 7,550 3.02K 474,042
24 Feb 21 James F Emigh Common Stock Option exercise Aquire M No No 0.151 20,000 3.02K 481,592
24 Feb 21 James F Emigh Stock options Common Stock Option exercise Dispose M No No 0.151 20,000 3.02K 0
24 Feb 21 Robert A Seiser Common Stock Payment of exercise Dispose F No No 0.4 7,550 3.02K 353,588
24 Feb 21 Robert A Seiser Common Stock Option exercise Aquire M No No 0.151 20,000 3.02K 361,138
24 Feb 21 Robert A Seiser Stock options Common Stock Option exercise Dispose M No No 0.151 20,000 3.02K 0
4 Jan 21 Robert A Seiser Common Stock Payment of exercise Dispose F No No 0.21 10,686 2.24K 341,138
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

ACUR institutional ownership history Ownership history
0.0% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 2 2 –
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
 Current Prev Q Change
Total value 0 0
Total shares 1.03K 1.03K –
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
Lenox Wealth Advisors 780 $0 0.0%
Captrust Financial Advisors 245 $0 0.0%
Largest transactions
 Shares Bought/sold Change
Captrust Financial Advisors 245 0 0.0%
Lenox Wealth Advisors 780 0 0.0%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Nektar Therapeutics • Elite Pharmaceuticals • Cassava Sciences • Acelrx Pharmaceuticals • KemPharm • Perrigo
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: alprazolam, imminent, inception, Intermediate, rescinded
Removed: discounting, optimized
From filing 10-Q 2020 Q3

Financial reports

View all
10-Q
2020 Q3
Quarterly report
16 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
28 Jun 20
10-K
2019 FY
Annual report
30 Mar 20
NT 10-K
Notice of late annual filing
30 Mar 20
10-Q
2019 Q3
Quarterly report
28 Feb 20
10-Q
2019 Q2
Quarterly report
10 Feb 20
NT 10-Q
Notice of late quarterly filing
8 Nov 19
10-Q
2019 Q1
Quarterly report
1 Oct 19
10-K
2018 FY
Annual report
16 Sep 19

Current reports

View all
8-K
Acura Pharmaceuticals Announces Third Quarter 2020 Financial Results
17 Nov 20
8-K
Entry into a Material Definitive Agreement
29 Oct 20
8-K
Acura Pharmaceuticals Announces Second Quarter 2020 Financial Results
17 Aug 20
8-K
Acura Pharmaceuticals Announces First Quarter 2020 Financial Results
30 Jun 20
8-K
Other Events
13 May 20
8-K
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results
1 Apr 20
8-K
Acura Pharmaceuticals Announces Third Quarter 2019 Financial Results
17 Mar 20
8-K
Acura Pharmaceuticals Announces Second Quarter 2019 Financial Results
12 Feb 20
8-K
Acura Pharmaceuticals Provides an Update
2 Jan 20
8-K
Acura Pharmaceuticals Announces First Quarter 2019 Financial Results
4 Oct 19

Registration and prospectus

View all
RW
Registration withdrawal request
31 Jul 18
S-8
Registration of securities for employees
16 Nov 17
D
$4M in equity / options / securities to be acquired, sold $4M, 1 investor
27 Jul 17
25-NSE
Exchange delisting
13 Mar 17
S-1
IPO registration
2 Feb 17
S-8
Registration of securities for employees
8 Aug 16
S-3/A
Shelf registration (amended)
22 Mar 16
S-3
Shelf registration
8 Mar 16
424B5
Prospectus supplement for primary offering
30 Jun 15
S-8
Registration of securities for employees
30 Apr 14

Proxies

View all
DEF 14A
Definitive proxy
26 Sep 17
DEFA14A
Additional proxy soliciting materials
26 Sep 17
DEFA14A
Additional proxy soliciting materials
12 Apr 16
DEF 14A
Definitive proxy
6 Mar 16
DEFA14A
Additional proxy soliciting materials
6 Mar 16
DEFA14A
Additional proxy soliciting materials
20 Jul 15
DEF 14A
Definitive proxy
13 Jul 15
PRE 14A
Preliminary proxy
21 Jun 15
DEF 14A
Definitive proxy
17 Mar 15
DEFA14A
Additional proxy soliciting materials
17 Mar 15

Other

View all
CT ORDER
Confidential treatment order
9 Apr 18
CT ORDER
Confidential treatment order
14 Jun 17
EFFECT
Notice of effectiveness
29 Mar 16
CORRESP
Correspondence with SEC
24 Mar 16
UPLOAD
Letter from SEC
17 Mar 16
CT ORDER
Confidential treatment order
23 Feb 16
CT ORDER
Confidential treatment order
4 May 15
UPLOAD
Letter from SEC
16 Oct 14
CORRESP
Correspondence with SEC
14 Oct 14
CORRESP
Correspondence with SEC
28 Sep 14

Ownership

View all
4
ACURA PHARMACEUTICALS / Robert A Seiser ownership change
26 Feb 21
4
ACURA PHARMACEUTICALS / JAMES F EMIGH ownership change
26 Feb 21
4
ACURA PHARMACEUTICALS / PETER A CLEMENS ownership change
26 Feb 21
4
ACURA PHARMACEUTICALS / IMMANUEL THANGARAJ ownership change
12 Jan 21
4
ACURA PHARMACEUTICALS / GEORGE K ROSS ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / BRUCE F WESSON ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / WILLIAM G SKELLY ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / Robert A Seiser ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / Robert B Jones ownership change
6 Jan 21
4
ACURA PHARMACEUTICALS / JAMES F EMIGH ownership change
6 Jan 21

Patents

View all
APP
Utility
Methods and Compositions for Self-regulated Release of Active Pharmaceutical Ingredient
2 Dec 20
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
GRANT
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
22 Jun 20
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
APP
Utility
Methods and Compositions for Interfering with Extraction or Conversion of a Drug Susceptible to Abuse
17 Jun 20
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
GRANT
Utility
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
6 Apr 20
Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse.
GRANT
Utility
Methods and compositions for self-regulated release of active pharmaceutical ingredient
14 Oct 19
An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.